Choice of aHUS treatments
In making a choice aHUS patients’ preferences among treatments like eculizumab (and its biosimulars) , ravulizumab, crovalimab, and iptacopan it largely…
AIRG Suisse: Their aHUS Survey
Our aHUS Alliance Global Action team takes to heart our mission to “Inform. Connect. Collaborate” on ideas and initiatives across all…
Discontinuing complement inhibitor treatment
It is now just over 3 months since a discontinuing treatment decision making model was proposed to help aHUS patients make…
Why the kidney – blame the complosome?
Intracellular complement, or “complosome,” refers to the complement system’s activity within cells, a discovery that has significantly expanded the understanding of…
Out with old in with the new- not quite just yet
On the 10th anniversary of international aHUS awareness day it is timely to raise awareness that the old term aHUS is…
The first ever aHUS research study patient cohort
The Global Action website has been featuring the pioneers and first events of aHUS history in its series Before aHUS Endeavours…
Atypical HUS Facts: 2024 – Sept – 2025
2024 – SEPT – 2025 Atypical HUS: Fact Sheets & Research Atypical Hemolytic Uremic Syndrome – a Rare Disease Information…
Social media and aHUS- Before aHUS endeavours fade
aHUS in the social media is now much more commonplace. In this latest article in the series “Before aHUS Endeavours Fade”…
Trial Watch 20- ClinicalTrials.eu
The Global Action series “Trial Watch” has in the past covered several trials of treatments for aHUS patients and even some…